The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort

The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort

Little is known about the value of adding concurrent chemotherapy (CC) to radiotherapy for stage II nasopharyngeal carcinoma (NPC) with undetectable (0 copies/mL) pretreatment Epstein-Barr Virus (EBV) DNA in the intensity-modulated radiotherapy (IMRT) era. To address this question, the present study...

Full description

Bibliographic Details
Main Authors: Ya-Nan Jin, Qing-Nan Tang, Ji-Jin Yao, Xi-Wei Xu, Wen-Zhuo He, Lei Wang, Ya-Fei You, Kun-Wei Peng, Chang Jiang, Liang-Ping Xia
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Translational Oncology
Subjects:
Nasopharyngeal carcinoma
Epstein–Barr virus DNA
Survival
Intensity-modulated radiotherapy
Concurrent chemotherapy
Effect
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320304824

Internet

http://www.sciencedirect.com/science/article/pii/S1936523320304824

Similar Items